Prostate cancer early detection

Mark H. Kawachi, Robert R. Bahnson, Michael Barry, Peter R. Carroll, H. Ballentine Carter, William J. Catalona, Jonathan I. Epstein, Ruth B. Etzioni, George P. Hemstreet, Richard J. Howe, Jeff D. Kopin, Paul H. Lange, Hans Lilja, James Mohler, Judd Moul, Robert B. Nadler, Stephan Patterson, Alan Pollack, Joseph C. Presti, Antoinette M. StroupDonald A. Urban, Robert Wake, John T. Wei

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Since the early 1990s when the ACS developed guidelines for the early detection of prostate cancer, many variants of the tPSA assay have been introduced to increase the sensitivity of screening programs (cancer detection) while maintaining specificity (elimination of unnecessary biopsies). Again, the NCCN guidelines recommend how individuals and their physicians can use these new methods rationally for the early detection of prostate cancer. These guidelines are not designed to provide an argument for using early detection programs for prostate cancer, but are meant to provide a vehicle with which early detection efforts can be practiced in an evidence-based, systematic fashion in patients who choose to participate in these programs.56 These NCCN guidelines incorporate many new validated findings in addition to the DRE and tPSA test. These new factors include percent fPSA, PSAV, cPSA, biopsy pathology, and TRUS-guided biopsy techniques. The panel will re-examine the clinical usefulness of these new modalities annually, and the guidelines will be modified accordingly. In addition, future iterations of these guidelines may incorporate new serum markers currently undergoing clinical investigation. The goal of the NCCN and this guideline panel in updating these algorithms is to help men and clinicians choose a program of early detection of prostate cancer and make decisions about the need for prostate biopsy. Any clinician who uses these guidelines is expected to exercise independent medical judgment in the context of the individual clinical circumstances to determine each patient's need for prostate biopsy. These guidelines will continue to evolve as the field of prostate cancer advances.

Original languageEnglish
Pages (from-to)714-736
Number of pages23
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume5
Issue number7
StatePublished - Aug 1 2007
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Guidelines
Early Detection of Cancer
Biopsy
Prostate
Biomarkers
Exercise
Pathology
Physicians

Keywords

  • Biopsy
  • Carcinoma screening
  • Early detection
  • NCCN Clinical Practice Guidelines
  • Prostate cancer
  • Prostate-specific antigen

ASJC Scopus subject areas

  • Oncology

Cite this

Kawachi, M. H., Bahnson, R. R., Barry, M., Carroll, P. R., Carter, H. B., Catalona, W. J., ... Wei, J. T. (2007). Prostate cancer early detection. JNCCN Journal of the National Comprehensive Cancer Network, 5(7), 714-736.

Prostate cancer early detection. / Kawachi, Mark H.; Bahnson, Robert R.; Barry, Michael; Carroll, Peter R.; Carter, H. Ballentine; Catalona, William J.; Epstein, Jonathan I.; Etzioni, Ruth B.; Hemstreet, George P.; Howe, Richard J.; Kopin, Jeff D.; Lange, Paul H.; Lilja, Hans; Mohler, James; Moul, Judd; Nadler, Robert B.; Patterson, Stephan; Pollack, Alan; Presti, Joseph C.; Stroup, Antoinette M.; Urban, Donald A.; Wake, Robert; Wei, John T.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 5, No. 7, 01.08.2007, p. 714-736.

Research output: Contribution to journalArticle

Kawachi, MH, Bahnson, RR, Barry, M, Carroll, PR, Carter, HB, Catalona, WJ, Epstein, JI, Etzioni, RB, Hemstreet, GP, Howe, RJ, Kopin, JD, Lange, PH, Lilja, H, Mohler, J, Moul, J, Nadler, RB, Patterson, S, Pollack, A, Presti, JC, Stroup, AM, Urban, DA, Wake, R & Wei, JT 2007, 'Prostate cancer early detection', JNCCN Journal of the National Comprehensive Cancer Network, vol. 5, no. 7, pp. 714-736.
Kawachi MH, Bahnson RR, Barry M, Carroll PR, Carter HB, Catalona WJ et al. Prostate cancer early detection. JNCCN Journal of the National Comprehensive Cancer Network. 2007 Aug 1;5(7):714-736.
Kawachi, Mark H. ; Bahnson, Robert R. ; Barry, Michael ; Carroll, Peter R. ; Carter, H. Ballentine ; Catalona, William J. ; Epstein, Jonathan I. ; Etzioni, Ruth B. ; Hemstreet, George P. ; Howe, Richard J. ; Kopin, Jeff D. ; Lange, Paul H. ; Lilja, Hans ; Mohler, James ; Moul, Judd ; Nadler, Robert B. ; Patterson, Stephan ; Pollack, Alan ; Presti, Joseph C. ; Stroup, Antoinette M. ; Urban, Donald A. ; Wake, Robert ; Wei, John T. / Prostate cancer early detection. In: JNCCN Journal of the National Comprehensive Cancer Network. 2007 ; Vol. 5, No. 7. pp. 714-736.
@article{1c15ddcaf5da4771aa19600707b5a857,
title = "Prostate cancer early detection",
abstract = "Since the early 1990s when the ACS developed guidelines for the early detection of prostate cancer, many variants of the tPSA assay have been introduced to increase the sensitivity of screening programs (cancer detection) while maintaining specificity (elimination of unnecessary biopsies). Again, the NCCN guidelines recommend how individuals and their physicians can use these new methods rationally for the early detection of prostate cancer. These guidelines are not designed to provide an argument for using early detection programs for prostate cancer, but are meant to provide a vehicle with which early detection efforts can be practiced in an evidence-based, systematic fashion in patients who choose to participate in these programs.56 These NCCN guidelines incorporate many new validated findings in addition to the DRE and tPSA test. These new factors include percent fPSA, PSAV, cPSA, biopsy pathology, and TRUS-guided biopsy techniques. The panel will re-examine the clinical usefulness of these new modalities annually, and the guidelines will be modified accordingly. In addition, future iterations of these guidelines may incorporate new serum markers currently undergoing clinical investigation. The goal of the NCCN and this guideline panel in updating these algorithms is to help men and clinicians choose a program of early detection of prostate cancer and make decisions about the need for prostate biopsy. Any clinician who uses these guidelines is expected to exercise independent medical judgment in the context of the individual clinical circumstances to determine each patient's need for prostate biopsy. These guidelines will continue to evolve as the field of prostate cancer advances.",
keywords = "Biopsy, Carcinoma screening, Early detection, NCCN Clinical Practice Guidelines, Prostate cancer, Prostate-specific antigen",
author = "Kawachi, {Mark H.} and Bahnson, {Robert R.} and Michael Barry and Carroll, {Peter R.} and Carter, {H. Ballentine} and Catalona, {William J.} and Epstein, {Jonathan I.} and Etzioni, {Ruth B.} and Hemstreet, {George P.} and Howe, {Richard J.} and Kopin, {Jeff D.} and Lange, {Paul H.} and Hans Lilja and James Mohler and Judd Moul and Nadler, {Robert B.} and Stephan Patterson and Alan Pollack and Presti, {Joseph C.} and Stroup, {Antoinette M.} and Urban, {Donald A.} and Robert Wake and Wei, {John T.}",
year = "2007",
month = "8",
day = "1",
language = "English",
volume = "5",
pages = "714--736",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "7",

}

TY - JOUR

T1 - Prostate cancer early detection

AU - Kawachi, Mark H.

AU - Bahnson, Robert R.

AU - Barry, Michael

AU - Carroll, Peter R.

AU - Carter, H. Ballentine

AU - Catalona, William J.

AU - Epstein, Jonathan I.

AU - Etzioni, Ruth B.

AU - Hemstreet, George P.

AU - Howe, Richard J.

AU - Kopin, Jeff D.

AU - Lange, Paul H.

AU - Lilja, Hans

AU - Mohler, James

AU - Moul, Judd

AU - Nadler, Robert B.

AU - Patterson, Stephan

AU - Pollack, Alan

AU - Presti, Joseph C.

AU - Stroup, Antoinette M.

AU - Urban, Donald A.

AU - Wake, Robert

AU - Wei, John T.

PY - 2007/8/1

Y1 - 2007/8/1

N2 - Since the early 1990s when the ACS developed guidelines for the early detection of prostate cancer, many variants of the tPSA assay have been introduced to increase the sensitivity of screening programs (cancer detection) while maintaining specificity (elimination of unnecessary biopsies). Again, the NCCN guidelines recommend how individuals and their physicians can use these new methods rationally for the early detection of prostate cancer. These guidelines are not designed to provide an argument for using early detection programs for prostate cancer, but are meant to provide a vehicle with which early detection efforts can be practiced in an evidence-based, systematic fashion in patients who choose to participate in these programs.56 These NCCN guidelines incorporate many new validated findings in addition to the DRE and tPSA test. These new factors include percent fPSA, PSAV, cPSA, biopsy pathology, and TRUS-guided biopsy techniques. The panel will re-examine the clinical usefulness of these new modalities annually, and the guidelines will be modified accordingly. In addition, future iterations of these guidelines may incorporate new serum markers currently undergoing clinical investigation. The goal of the NCCN and this guideline panel in updating these algorithms is to help men and clinicians choose a program of early detection of prostate cancer and make decisions about the need for prostate biopsy. Any clinician who uses these guidelines is expected to exercise independent medical judgment in the context of the individual clinical circumstances to determine each patient's need for prostate biopsy. These guidelines will continue to evolve as the field of prostate cancer advances.

AB - Since the early 1990s when the ACS developed guidelines for the early detection of prostate cancer, many variants of the tPSA assay have been introduced to increase the sensitivity of screening programs (cancer detection) while maintaining specificity (elimination of unnecessary biopsies). Again, the NCCN guidelines recommend how individuals and their physicians can use these new methods rationally for the early detection of prostate cancer. These guidelines are not designed to provide an argument for using early detection programs for prostate cancer, but are meant to provide a vehicle with which early detection efforts can be practiced in an evidence-based, systematic fashion in patients who choose to participate in these programs.56 These NCCN guidelines incorporate many new validated findings in addition to the DRE and tPSA test. These new factors include percent fPSA, PSAV, cPSA, biopsy pathology, and TRUS-guided biopsy techniques. The panel will re-examine the clinical usefulness of these new modalities annually, and the guidelines will be modified accordingly. In addition, future iterations of these guidelines may incorporate new serum markers currently undergoing clinical investigation. The goal of the NCCN and this guideline panel in updating these algorithms is to help men and clinicians choose a program of early detection of prostate cancer and make decisions about the need for prostate biopsy. Any clinician who uses these guidelines is expected to exercise independent medical judgment in the context of the individual clinical circumstances to determine each patient's need for prostate biopsy. These guidelines will continue to evolve as the field of prostate cancer advances.

KW - Biopsy

KW - Carcinoma screening

KW - Early detection

KW - NCCN Clinical Practice Guidelines

KW - Prostate cancer

KW - Prostate-specific antigen

UR - http://www.scopus.com/inward/record.url?scp=34547961147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547961147&partnerID=8YFLogxK

M3 - Article

C2 - 17692177

AN - SCOPUS:34547961147

VL - 5

SP - 714

EP - 736

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 7

ER -